Global Roundup: EU Approves ViiV's HIV-1 Drug and More
Published: Dec 24, 2020 By Alex Keown The European Union (EU) authorized ViiV Healthcare’s Vocabria (cabotegravir injection and tablets) in conjunction with Janssen’s Edurant (rilpivirine tablets) for the treatment of HIV-1 infection in adults who are virologically suppressed. Vocabria is intended for adults who are virologically suppressed on a stable antiretroviral regimen without present or past evidence of viral resistance to, and no prior virological failure with agents of the NNRTI and INI class. The approval of ViiV’s treatment is the first time HIV-1 patients in Europe m...